Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO,Calif.,and SUZHOU and SHANGHAI,China,Oct. 24,2022 --Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"),a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,today announced that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022 as follows:

Credit Suisse 31st Annual Healthcare Conference 2022

One-on-one meetings: Tuesday,November 8,2022

Location: Rancho Palos Verdes,CA

Jefferies London Healthcare Conference 2022

Fireside Chat: November 15 at 2:40 pm GMT

One-on-one meetings: Tuesday,November 15,2022

Location: London,UK

A webcast of the fireside chat will be available on the News and Eventssection of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module,Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies,including lengthy manufacturing time,suboptimal cell quality,high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell,please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-two-upcoming-investor-conferences-301656844.html